KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Retained Earnings (2018 - 2025)

Vir Biotechnology's Retained Earnings history spans 8 years, with the latest figure at -$2.1 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 99.73% year-over-year to -$2.1 million; the TTM value through Dec 2025 reached -$2.1 million, up 99.73%, while the annual FY2025 figure was -$2.1 million, 99.73% up from the prior year.
  • Retained Earnings for Q4 2025 was -$2.1 million at Vir Biotechnology, up from -$1.2 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $774.3 million in Q2 2021 and bottomed at -$1.2 billion in Q3 2025.
  • The 5-year median for Retained Earnings is -$2.0 million (2025), against an average of -$1.4 million.
  • The largest annual shift saw Retained Earnings surged 36736.57% in 2022 before it crashed 102570.98% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$138.6 million in 2021, then surged by 93.42% to -$9.1 million in 2022, then soared by 91.07% to -$815000.0 in 2023, then plummeted by 93125.03% to -$759.8 million in 2024, then skyrocketed by 99.73% to -$2.1 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Retained Earnings are -$2.1 million (Q4 2025), -$1.2 billion (Q3 2025), and -$2.2 million (Q2 2025).